{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:20Z","timestamp":1790470220713,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T00:00:00Z","timestamp":1608940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["81870480"],"award-info":[{"award-number":["81870480"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["U1604186"],"award-info":[{"award-number":["U1604186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1314002"],"award-info":[{"award-number":["2018YFC1314002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Malignant nephrosclerosis, defined as renal microangiopathy in the setting of severe hypertension, remains a critical renal emergency leading to end-stage renal disease despite aggressive anti-hypertensive treatment. Recently, activation of the complement alternative pathway (AP) has been reported to play a prominent role in the pathogenesis of malignant nephrosclerosis. However, subsequent study failed to recapitulate the findings of genetic complement abnormalities in the disease. This study aimed to determine the presence of AP activation and genetic complement defects and establish their correlations to renal microangiopathy lesions, clinical features and prognosis in patients with malignant nephrosclerosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fifty patients with malignant hypertension and concomitant thrombotic microangiopathy (TMA) proven by renal biopsy were investigated; 25 cases of kidney donors who received zero-hour allograft biopsies were used as normal controls. Various renal TMA lesions in patients with malignant nephrosclerosis were reviewed and evaluated using a semi-quantitative scoring system. Deposition of C5b-9, C3a, C5a, C4d and mannose-binding lectin was assessed by immunohistochemistry. Co-localization of C5b-9 and CD34 was detected by confocal microscopy. Complement factor B (FB), factor P (FP; properdin), factor D (FD), factor H (FH), C3a and C5a levels were quantified by enzyme-linked immonosorbent assay in plasma and urine samples of patients with malignant nephrosclerosis and controls. Genetic abnormalities of complement components were analysed by whole-exome sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Renal biopsies of malignant nephrosclerosis showed identical histopathological and ultrastructural features to atypical haemolytic uraemic syndrome. C5b-9, C3a and C5a deposits were found along the walls of arteries\/arterioles and glomerular capillaries and localized in the endothelial cells. Elevated plasma and urinary levels of FB, FP, FD, C3a and C5a as well as decreased FH levels were observed in patients with malignant nephrosclerosis compared with normal controls. The urinary levels of complement AP components, but not the plasma levels, were correlated with renal functions, prognosis and active TMA lesions except for arteriolar thrombi. Finally, mutations of the MCP, CFB, CFH and CFHR5 genes were identified in 8 of 20 patients with malignant nephrosclerosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Aberrant complement AP dysregulation was demonstrated and associated with the activity, severity and renal outcomes of malignant nephrosclerosis. This observation warrants screening for complement defects in patients with malignant nephrosclerosis for the potential use of complement regulators and also highlights the need for further investigation of the precise role of AP in the pathogenesis of the disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa280","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T11:10:15Z","timestamp":1602846615000},"page":"1222-1233","source":"Crossref","is-referenced-by-count":24,"title":["Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis"],"prefix":"10.1093","volume":"36","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaona","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Renal Path Diagnostics at Pathologists BioMedical Laboratories, Lewisville, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songxia","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,26]]},"reference":[{"key":"2021062815223954400_gfaa280-B1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/00004872-199411000-00013","article-title":"The failure of malignant hypertension to decline: a survey of 24 years\u2019 experience in a multiracial population in England","volume":"12","author":"Lip","year":"1994","journal-title":"J Hypertens"},{"key":"2021062815223954400_gfaa280-B2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ajh.2009.153","article-title":"Improving survival of malignant hypertension patients over 40 years","volume":"22","author":"Lane","year":"2009","journal-title":"Am J Hypertens"},{"key":"2021062815223954400_gfaa280-B3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ajh\/hpx008","article-title":"Malignant hypertension revisited-does this still exist?","volume":"30","author":"Shantsila","year":"2017","journal-title":"Am J Hypertens"},{"key":"2021062815223954400_gfaa280-B4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","article-title":"Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort","volume":"37","author":"Rubin","year":"2019","journal-title":"J Hypertens"},{"key":"2021062815223954400_gfaa280-B5","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1093\/ndt\/gfq143","article-title":"Long-term renal survival in malignant hypertension","volume":"25","author":"Gonzalez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2021062815223954400_gfaa280-B6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"key":"2021062815223954400_gfaa280-B7","first-page":"51","article-title":"Cardiovascular hypertensive crisis: recent evidence and review of the literature","volume":"3","author":"Varounis","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"2021062815223954400_gfaa280-B8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0002-9440(10)64445-8","article-title":"Immunosuppressive treatment protects against angiotensin II-induced renal damage","volume":"161","author":"Muller","year":"2002","journal-title":"Am J Pathol"},{"key":"2021062815223954400_gfaa280-B9","doi-asserted-by":"crossref","first-page":"H349","DOI":"10.1152\/ajpheart.00759.2016","article-title":"A pathogenic role of complement in arterial hypertension and hypertensive end organ damage","volume":"312","author":"Wenzel","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2021062815223954400_gfaa280-B10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J"},{"key":"2021062815223954400_gfaa280-B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J Nephrol"},{"key":"2021062815223954400_gfaa280-B12","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2021062815223954400_gfaa280-B13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod Pathol"},{"key":"2021062815223954400_gfaa280-B14","volume-title":"Heptinstall's Pathology of the Kidney, 7th edn","author":"Jennette","year":"2004"},{"key":"2021062815223954400_gfaa280-B15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00467-016-3562-7","article-title":"The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"32","author":"Song","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2021062815223954400_gfaa280-B16","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3109\/14767058.2012.694923","article-title":"The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome","volume":"25","author":"Crovetto","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2021062815223954400_gfaa280-B17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000445127","article-title":"Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome","volume":"43","author":"Zhang","year":"2016","journal-title":"Am J Nephrol"},{"key":"2021062815223954400_gfaa280-B18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"2021062815223954400_gfaa280-B19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1291\/hypres.31.479","article-title":"Renal thrombotic microangiopathies induced by severe hypertension","volume":"31","author":"Zhang","year":"2008","journal-title":"Hypertens Res"},{"key":"2021062815223954400_gfaa280-B20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5414\/CNP73147","article-title":"Severe renal failure and microangiopathic hemolysis induced by malignant hypertension\u2013case series and review of literature","volume":"73","author":"Shavit","year":"2010","journal-title":"Clin Nephrol"},{"key":"2021062815223954400_gfaa280-B21","doi-asserted-by":"crossref","first-page":"bcr2017220457","DOI":"10.1136\/bcr-2017-220457","article-title":"Malignant hypertension as a rare cause of thrombotic microangiopathy","volume":"2017","author":"Thind","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2021062815223954400_gfaa280-B22","first-page":"502","article-title":"Malignant hypertension complicated by renal thrombotic micro angiopathy: role of Adam 13 mutational analyses","volume":"29","author":"Aijazi","year":"2017","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"2021062815223954400_gfaa280-B23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"key":"2021062815223954400_gfaa280-B24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040620715571076","article-title":"Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura","volume":"6","author":"Khanal","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"2021062815223954400_gfaa280-B25","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/art.23662","article-title":"Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021062815223954400_gfaa280-B26","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1681\/ASN.2014050429","article-title":"Complement factor C4d is a common denominator in thrombotic microangiopathy","volume":"26","author":"Chua","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021062815223954400_gfaa280-B27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/tri.12936","article-title":"Glomerular C4d deposits can mark structural capillary wall remodelling in thrombotic microangiopathy and transplant glomerulopathy: C4d beyond active antibody-mediated injury: a retrospective study","volume":"30","author":"Gasim","year":"2017","journal-title":"Transpl Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/7\/1222\/38834098\/gfaa280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/7\/1222\/38834098\/gfaa280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T15:42:48Z","timestamp":1624894968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/7\/1222\/6050609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,26]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,26]]},"published-print":{"date-parts":[[2021,6,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa280","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,26]]}}}